GCT Manufacturing | Vector Production | Autologous and Allogeneic | Stem Cells | Supply Chain | Scalability & Management - 2021 World Medical Innovation Forum
Boston
May 2–4, 2022

GCT Manufacturing | Vector Production | Autologous and Allogeneic | Stem Cells | Supply Chain | Scalability & Management

GCT Manufacturing | Vector Production | Autologous and Allogeneic | Stem Cells | Supply Chain | Scalability & Management

Wednesday, May 19, 2021

4:00 PM – 4:25 PM

The modes of GCT manufacturing have the potential of fundamentally reordering long-established roles and pathways. While complexity goes up the distance from discovery to deployment shrinks. With the likelihood of a total market for cell therapies to be over $48 billion by 2027,  groups of products are emerging.  Stem cell therapies are projected to be $28 billion by 2027 and non-stem cell therapies such as CAR-T are projected be $20 billion by 2027. The manufacturing challenges for these two large buckets are very different. Within the CAR-T realm there are diverging trends of autologous and allogeneic therapies and the demands on manufacturing infrastructure are very different. Questions for the panelists are:

  • Help us all understand the different manufacturing challenges for cell therapies. What are the trade-offs among storage cost, batch size, line changes in terms of production cost and what is the current state of scaling naïve and stem cell therapy treatment vs engineered cell therapies?
  • For cell and gene therapy what is the cost of Quality Assurance/Quality Control vs. production and how do you think this will trend over time based on your perspective on learning curves today?
  • Will point of care production become a reality? How will that change product development strategy for pharma and venture investors? What would be the regulatory implications for such products?
  • How close are allogeneic CAR-T cell therapies? If successful what are the market implications of allogenic CAR-T? What are the cost implications and rewards for developing allogeneic cell therapy treatments?
Moderator:
Michael Paglia
  • COO, ElevateBio BaseCamp, ElevateBio
Speakers:
Thomas Page, PhD
  • VP, Engineering and Asset Development, FUJIFILM Diosynth Biotechnologies
Rupa Pike, PhD
  • Director, Enterprise Science & Innovation Partnerships, Thermo Fisher Scientific
Rahul Singhvi, ScD
  • CEO and Co-Founder, National Resilience, Inc.
Thomas VanCott, PhD
  • Chief Technology & Strategy Officer, Catalent Cell & Gene Therapy
  • Q&A

    04:30 PM – 04:45 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA